Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MCL1 | Q07820 | 7/20 | 0.39 |
| ▸ | FDFT1 | P37268 | 1/20 | 0.39 |
| ▸ | ATM | Q13315 | 2/20 | 0.38 |
| ▸ | ITGB1 | P05556 | 4/20 | 0.38 |
| ▸ | ITGA2 | P17301 | 4/20 | 0.38 |
| ▸ | ITGA4 | P13612 | 1/20 | 0.38 |
| ▸ | CFD | P00746 | 2/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13700636 | 0.94 | ITGB1 (0.39) | MCL1FDFT1ITGB1ITGA2ITGA4 | |
| SCHEMBL12084396 | 0.88 | CFD (0.38) | MCL1FDFT1CFD | |
| SCHEMBL13700380 | 0.83 | ITGB1 (0.49) | ATMITGB1ITGA2ITGA4 | |
| SCHEMBL15111797 | 0.80 | CFD (0.41) | MCL1CFD | |
| SCHEMBL15111798 | 0.80 | CFD (0.41) | MCL1CFD | |
| SCHEMBL13700377 | 0.79 | ITGB1 (0.55) | MCL1ATMITGB1ITGA2ITGA4 | |
| SCHEMBL30849269 | 0.79 | KMT2A (0.39) | MCL1 | |
| SCHEMBL23824492 | 0.79 | CTSS (0.38) | — | |
| SCHEMBL23824493 | 0.79 | CTSS (0.38) | — | |
| SCHEMBL30009104 | 0.79 | CTSS (0.38) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090233968-A1 | INHIBITORS OF THE ALPHA2BETA1/GPIa-IIA INTEGRIN | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 2009-09-17 | — | — | US | disclosed |
| WO-2006133338-A1 | INHIBITORS OF THE α2β1/GPIa-IIa INTEGRIN | THE TRUSTEES OF THE UNIVERSITY OF PENNESYLVANIA (US) | 2006-12-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090233968-A1 | INHIBITORS OF THE ALPHA2BETA1/GPIa-IIA INTEGRIN | ITGA2B, ITGB2, ITGA2 | MCL1 2112/4885FDFT1 4219/4885ATM 4309/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.